newsA potentially first-in-class PKC theta inhibitor, in development for immunology…
6 February 2023 | By Catherine Eckford (European Pharmaceutical Review)
A potentially first-in-class PKC theta inhibitor, in development for immunology and inflammation indications, has entered first-in-human trials in the US.